0001714899-23-000055.txt : 20230414
0001714899-23-000055.hdr.sgml : 20230414
20230414182713
ACCESSION NUMBER: 0001714899-23-000055
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230412
FILED AS OF DATE: 20230414
DATE AS OF CHANGE: 20230414
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schuth Alexander O.
CENTRAL INDEX KEY: 0001724311
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38311
FILM NUMBER: 23822368
MAIL ADDRESS:
STREET 1: C/O DENALI THERAPEUTICS INC.
STREET 2: 151 OYSTER POINT BLVD., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Denali Therapeutics Inc.
CENTRAL INDEX KEY: 0001714899
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463872213
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 866-8548
MAIL ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
wf-form4_168151121787982.xml
FORM 4
X0407
4
2023-04-12
0
0001714899
Denali Therapeutics Inc.
DNLI
0001724311
Schuth Alexander O.
C/O DENALI THERAPEUTICS INC.
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
COFO and Secretary
0
Common Stock
2023-04-12
4
M
0
5102
5.28
A
533793
I
See footnote
Common Stock
2023-04-12
4
S
0
5102
25.04
D
528691
I
See footnote
Common Stock
2023-04-13
4
M
0
4898
5.28
A
533589
I
See footnote
Common Stock
2023-04-13
4
S
0
4898
25.04
D
528691
I
See footnote
Common Stock
130792
D
Stock Option (right to buy)
5.28
2023-04-12
4
M
0
5102
0
D
2027-03-07
Common Stock
5102.0
93835
D
Stock Option (right to buy)
5.28
2023-04-13
4
M
0
4898
0
D
2027-03-07
Common Stock
4898.0
88937
D
Exercised shares were issued to the Schuth Family Trust.
The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Includes 119,156 RSUs.
25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter.
/s/ Tyler Nielsen, by power of attorney
2023-04-14